Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galapagos ADR Representing Ord Shs GLPG

Healthcare Biotechnology
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of... see more

Recent & Breaking News (NDAQ:GLPG)

Galapagos raises $338 million gross proceeds in a U.S. public offering

GlobeNewswire April 17, 2017

Galapagos announces launch of proposed public offering

GlobeNewswire April 17, 2017

Galapagos increases share capital through warrant exercises

GlobeNewswire April 6, 2017

Galapagos doses first psoriatic arthritis patient with filgotinib

GlobeNewswire April 5, 2017

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

GlobeNewswire April 4, 2017

Publication of the annual report and invitation to the annual and extraordinary shareholders' meetings

GlobeNewswire March 23, 2017

Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067

GlobeNewswire March 22, 2017

New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

GlobeNewswire March 10, 2017

Galapagos reports strong financial results and newsflow-rich pipeline

GlobeNewswire February 23, 2017

Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451

GlobeNewswire February 23, 2017

Galapagos doses first patient with novel CF corrector GLPG2222

GlobeNewswire February 1, 2017

Galapagos creates new warrant plan

GlobeNewswire January 20, 2017

Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer

GlobeNewswire January 17, 2017

SAPHIRA 1 topline shows competitive clinical results in G551D patients

GlobeNewswire December 20, 2016

Start Phase 2b/3 study with filgotinib in ulcerative colitis

GlobeNewswire December 8, 2016

Galapagos increases share capital through warrant exercises

GlobeNewswire November 29, 2016

Galapagos initiates Phase 1 study with cystic fibrosis drug GLPG2737

GlobeNewswire November 28, 2016

Galapagos selected for Stoxx Europe 600 Index

GlobeNewswire November 24, 2016

Phase 3 study with filgotinib initiated in Crohn's disease

GlobeNewswire November 22, 2016

Robust progress in Q3 2016

GlobeNewswire October 27, 2016